NEWS
Print Your Certificate
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Daniel Dysart Pearce
i
Loma Linda University - Loma Linda / United States
Others
AD Scientific Index ID: 1345014
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Daniel Dysart Pearce's MOST POPULAR ARTICLES
1-)
Major clinical outcomes in antiretroviral therapy (ART)–naive participants and in those not receiving ART at baseline in the SMART studyStrategies for Management of Antiretroviral Therapy (SMART) Study GroupThe Journal of infectious diseases 197 (8), 1133-1144, 20085562008
2-)
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDSSD Nightingale, DW Cameron, FM Gordin, PM Sullam, DL Cohn, ...New England Journal of Medicine 329 (12), 828-833, 19934721993
3-)
Inferior Clinical Outcome of the CD4+ Cell Count–Guided Antiretroviral Treatment Interruption Strategy in the SMART Study: Role of CD4+ Cell Counts and HIV …Strategies for Management of Antiretroviral Therapy (SMART) Study GroupThe Journal of infectious diseases 197 (8), 1145-1155, 20082432008
4-)
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsFD Tattersall, W Rycroft, B Francis, D Pearce, K Merchant, AM MacLeod, ...Neuropharmacology 35 (8), 1121-1129, 19962491996
5-)
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trialMS Saag, P Cahn, F Raffi, M Wolff, D Pearce, JM Molina, W Powderly, ...Jama 292 (2), 180-189, 20042182004
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept